Shanghai, China, December 23 2020 — Shanghai Horizon Medical Technology Co., Ltd. (HorizonMedical™) has been identified as a National High-tech Enterprise, this was announced recently in the “Notice on the Public Announcement of the Fourth Batch of High-tech Enterprises 2020” issued by the National Administration Office of High-tech Enterprise Recognition.
High-tech Enterprises are resident innovative entities that are registered in China (excluding Hong Kong, Macao and Taiwan), committed to the research, development and commercialization of technological achievements in the fields defined in High and New Tech Fields under the Key Support of the State. They are enterprises that have developed independent core intellectual property rights on which basis their operations are undertaken.
By supporting and encouraging the development of high and new tech enterprises, it is possible to promote widespread entrepreneurship and innovation, cultivate fresh ideas to develop new technologies, create new types of business and provide new supplies, thus promoting economic upgrading and development. High-tech Enterprises requires high standards that HorizonMedical™ has met and been identified as having achieved.
At present, the LotusTM single lumen oocyte retrieval needle and Daylily™ embryo transfer catheter, two proprietary products developed by HorizonMedical™, have been approved for marketing and launched in China. The selection of HorizonMedical™ as a High-tech Enterprise signifies the recognition by the authorities on the company’s innovation system, independent innovation capability and comprehensive management strength. In the future, HorizonMedical™ will continue its efforts on innovative research and development, strengthen its core competitiveness, and reach out to more domestic and international markets. This enhances the commitment to becoming a total solutions provider of ART that will bring wider hope for more families and their chance to welcome new lives into the world.
About Shanghai MicroPort Horizon Medical Technology Co., Ltd.
Founded in November 2018, HorizonMedical™ is focused on medical solutions in the field of assisted reproductive technology (ART). Its business covers the R&D, manufacturing, marketing, and technical support of products at every step of the ART treatment process, including egg and sperm collection, fertilization, embryo culture, cryopreservation, and embryo transfer. HorizonMedical™ has already established strong relationships and collaborations with many well-known IVF centers and universities across China, and it continues to engage with doctors and engineers to research and develop innovative products, to create a sound and open environment for innovation, and accelerate the commercialization and application of innovative medical products in the field of ART.